FDA Approves PharmaEssentia’s Besremi for Essential Thrombocythaemia

As reported on Pharmaceutical Technology, the US Food and Drug Administration (FDA) has granted approval to PharmaEssentia’s Besremi (ropeginterferon alfa-2b-njft) for the treatment of adults with essential thrombocythaemia (ET), providing…

Continue Reading FDA Approves PharmaEssentia’s Besremi for Essential Thrombocythaemia

Virtual Event September 10th for Myeloproliferative Neoplasm International Awareness Day

Myeloproliferative neoplasm (MPN) International Awareness Day is on September 10th. This year, there will be a live streaming event to help bring awareness to this condition, instead of an in-person…

Continue Reading Virtual Event September 10th for Myeloproliferative Neoplasm International Awareness Day
Age at Myeloproliferative Neoplasm Diagnosis Has Little Impact on Mortality Risk Says New Study
qimono / Pixabay

Age at Myeloproliferative Neoplasm Diagnosis Has Little Impact on Mortality Risk Says New Study

According to a publication from Oncology Nurse Advisor, a study of 109 patients with myeloproliferative neoplasms (certain types of blood cancers) found that mortality rates for younger patients were similar…

Continue Reading Age at Myeloproliferative Neoplasm Diagnosis Has Little Impact on Mortality Risk Says New Study